Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells

Abstract

Previous studies have shown that mycophenolic acid (MPA) has an anti-HCV activity. However, the mechanism of MPA-mediated inhibition of HCV replication remains to be determined. This study investigated whether MPA has an effect on autophagy, a cellular machinery required for HCV replication, thereby, inhibits HCV replication in Huh7 cells. MPA treatment of Huh7 cells could suppress autophagy, evidenced by decreased LC3B-II level and conversion of LC3B-I to LC3B-II, decreased autophagosome formation, and increased p62 level compared to MPA-untreated cells. Tunicamycin treatment or HCV infection could induce cellular autophagy, however, MPA also exhibited its inhibitory effect on tunicamycin- or HCV infection-induced autophagy. The expression of three autophagy-related genes, Atg3, Atg5, and Atg7 were identified to be inhibited by MPA treatment. Over-expression of these genes could partly recover HCV replication inhibited by MPA; however, silencing their expression by siRNAs could enhance the inhibitory effect of MPA on HCV. Collectively, these results reveal that suppression of autophagy by MPA plays a role in its anti-HCV activity. Down-regulating the expression of three autophagy-related genes by MPA involves in its antiviral mechanism.

Quantitative Proteomic Analysis Reveals That Arctigenin Alleviates Concanavalin A-Induced Hepatitis Through Suppressing Immune System and Regulating Autophagy

“…The inhibition of autophagosome formation by 3-MA or siRNA targeting Beclin1 and Atg5 markedly inhibited HBV replication ( 131 ). Downregulation of the autophagy-related gene expressions by mycophenolic acid could also inhibit HCV replication ( 132 ). The autophagy inducer, rapamycin enhanced HBV replication ( 133 ), while an autophagy inhibitor chloroquine reduced viral as well as ALT levels ( 134 ).…”

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

“…The only evidence of the presence of another antiviral mechanism of MMF derives from a study on hepatitis C virus (HCV). It seems that the drug is able to inhibit in vitro and in vivo the virus replication by augmentation of IFN-stimulated gene expression [157], suppressing HuH-7 cell autophagy, decreasing autophagosome formation, and increasing p62 level expression in vitro [158]. MERS-CoV caused several fatal infections in the Middle East and traveler-associated cases in Europe and Africa with over 35% fatality since its emergence in 2012 [159].…”

Screening and evaluation of potential inhibitors against vaccinia virus from 767 approved drugs

“…The mechanism of MMF is inhibiting DNA synthesis through the repression of guanosine monophosphate de novo synthesis . MMF has been reported by previous in vitro and/or in vivo studies to be a broad spectrum antiviral agent against infections of influenza H5N1 or H7N9, hepatitis C virus, dengue, and Chikungunya virus . The antiviral activities of MMF against orthopoxviruses, such as camelpox (Somalia strain), cowpox (Brighton strain), monkeypox (Zaire strain), and VACV (Copenhagen strain), were validated by plaque reduction assays, but MMF failed to prevent death or extend the mean day of death from cowpox infection in mice …”